Core Viewpoint - The company has received approval from the National Medical Products Administration (NMPA) for clinical trial applications of HLX43 in combination with HLX07 and Hanshuo® for the treatment of advanced solid tumors [1][2] Group 1: Clinical Trial Approvals - The clinical trial application for HLX43, a PD-L1 targeted antibody-drug conjugate, in combination with HLX07 and Hanshuo® has been approved by NMPA [1] - The company plans to conduct the relevant clinical trials within China once conditions are met [1] Group 2: Clinical Data and Product Development - Phase 1 clinical data for HLX43 will be presented at the 2025 American Society of Clinical Oncology (ASCO) annual meeting and the 2025 World Lung Cancer Conference (WCLC), showing promising safety and preliminary efficacy in non-small cell lung cancer (NSCLC) and other solid tumors [2] - HLX07, an innovative biopharmaceutical targeting EGFR, has shown good safety and tolerability in a 1b/2 phase clinical study for advanced solid tumors conducted in February 2023 [2] - Hanshuo®, an innovative anti-PD-1 monoclonal antibody developed by the company, has been approved for multiple indications in mainland China, including first-line treatment for squamous NSCLC and extensive-stage small cell lung cancer [2] - The New Drug Application (NDA) for Hanshuo® in combination with chemotherapy for neoadjuvant/adjuvant treatment of gastric cancer has been accepted by NMPA and is under priority review [2]
复宏汉霖(02696)：注射用HLX43联合HLX07及汉斯状® 用于晚期实体瘤治疗的临床试验申请获国家药品监督管理局批准